Kalaris Therapeutics, Inc. (KLRS)
4.08
-0.07
(-1.69%)
USD |
NASDAQ |
Aug 24, 16:00
4.08
0.00 (0.00%)
After-Hours: 20:00
Kalaris Therapeutics Debt to Equity Ratio : 0.0243 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0243 |
| March 31, 2026 | 0.0206 |
| December 31, 2025 | 0.0184 |
| September 30, 2025 | 0.0369 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | -0.6821 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.0748 |
| March 31, 2024 | 0.1523 |
| December 31, 2023 | 0.1882 |
| September 30, 2023 | 0.1684 |
| June 30, 2023 | 0.1375 |
| March 31, 2023 | 0.1748 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.1576 |
| September 30, 2022 | 0.0856 |
| June 30, 2022 | 0.1423 |
| March 31, 2022 | 0.1207 |
| December 31, 2021 | 0.1335 |
| September 30, 2021 | 0.1173 |
| June 30, 2021 | 0.0303 |
| March 31, 2021 | 0.0309 |
| December 31, 2020 | 0.0246 |
| September 30, 2020 | 0.0253 |
| June 30, 2020 | 0.1006 |
| March 31, 2020 | 0.0973 |
| December 31, 2019 | 0.0967 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Replimune Group, Inc. | 1.060 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 99.54M |
| Total Liabilities (Quarterly) | 41.87M |
| Shareholders Equity (Quarterly) | 57.67M |
| Current Ratio | 10.92 |
| Net Debt Paydown Yield | -0.29% |